Massachusetts-based Theracos – not to be confused with Bay Area diagnostics company Theranos – just raised $25 million for its type 2 diabetes drug.
The company is developing a series of SGLT2 inhibitors as a potential drug to treat type 2 diabetes. It works by inhibiting the kidney’s ability to recover glucose that’s been excreted – thereby increasing the amount that is shed in urine, and decreasing the amount retained in the blood.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
The company is currently in the midst of recruiting participants with type 2 diabetes for a Phase 2b dosing trial. Its experimental drug, called bexagliflozin, has been tested in studies in the U.S., Europe, Russia and Japan.
It works in a similar manner to Farxiga, a popular AstraZeneca type 2 diabetes drug approved in 2014 that also works as an SGLT2 inhibitor. Other such drugs are Invokana and Jardiance.
[Image courtesy of Flickr user Bill David Brooks]